Santen, Tracon discontinue development of wet AMD treatment

Santen and Tracon Pharmaceuticals have discontinued development of DE-122, their wet age-related macular degeneration treatment candidate, following data analysis of a phase 2a study, the companies announced in a press release.

The randomized, controlled AVANTE clinical study evaluated visual acuity in wet AMD patients who had received six monthly DE-122 treatments with Lucentis (ranibizumab, Genentech) or Lucentis alone. Topline data found no improvement in visual acuity when DE-122 was added to Lucentis.

Santen licensed the development rights to DE-122 from Tracon in 2014. The discontinuation of its development is not expected to have a material impact on Santen’s fiscal year financial results, the release said.

Santen and Tracon Pharmaceuticals have discontinued development of DE-122, their wet age-related macular degeneration treatment candidate, following data analysis of a phase 2a study, the companies announced in a press release.

The randomized, controlled AVANTE clinical study evaluated visual acuity in wet AMD patients who had received six monthly DE-122 treatments with Lucentis (ranibizumab, Genentech) or Lucentis alone. Topline data found no improvement in visual acuity when DE-122 was added to Lucentis.

Santen licensed the development rights to DE-122 from Tracon in 2014. The discontinuation of its development is not expected to have a material impact on Santen’s fiscal year financial results, the release said.